These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 18806569)

  • 1. Cure of neuroendocrine carcinoma by peptide receptor radionuclide therapy.
    Zöphel K; Strumpf A; Wunderlich G; Oehme L; Eisenhofer G; Kotzerke J
    Clin Nucl Med; 2008 Oct; 33(10):690-1. PubMed ID: 18806569
    [No Abstract]   [Full Text] [Related]  

  • 2. Complete Remission of Metastatic Neuroendocrine Paragastric Carcinoma After "Neoadjuvant" Peptide Receptor Radionuclide Therapy and Surgery.
    Schmidt MC; Uhrhan K; Fischer T; Schmitz S; Markiefka B; Drzezga A; Stippel D
    Clin Nucl Med; 2015 Aug; 40(8):667-9. PubMed ID: 26053706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver and bone metastases from small bowel neuroendocrine tumor respond to 177Lu-DOTATATE induction and maintenance therapies.
    Makis W; McCann K; Buteau FA; McEwan AJ
    Clin Nucl Med; 2015 Feb; 40(2):162-5. PubMed ID: 25243941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective treatment of bone metastases from a neuroendocrine tumour of the pancreas with high activities of Indium-111-pentetreotide.
    van der Hiel B; Stokkel MP; Chiti A; Lucignani G; Bajetta E; Pauwels EK; Bombardieri E
    Eur J Endocrinol; 2003 Dec; 149(6):479-83. PubMed ID: 14640987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impressive Response to Tandem Treatment With [90Y]DOTATOC and [177Lu]DOTATOC in Grade 3 Pancreatic Neuroendocrine Carcinoma.
    Lorenzoni A; Capozza A; Artale S; Maccauro M; Seregni EC
    Clin Nucl Med; 2018 Jul; 43(7):506-508. PubMed ID: 29742602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Repeated Peptide Receptor Radionuclide Therapies in Renal Neuroendocrine Tumor With Osseous Metastasis.
    Yordanova A; Mayer K; Essler M; Ahmadzadehfar H
    Clin Nucl Med; 2016 Dec; 41(12):977-979. PubMed ID: 27749410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Case of Metastatic VIPoma With Complete Response to Peptide Radionuclide Receptor Therapy.
    Audil HY; Eiring RA; Kendi AT; Halfdanarson TR
    Pancreas; 2021 Apr; 50(4):e45-e46. PubMed ID: 33939683
    [No Abstract]   [Full Text] [Related]  

  • 8. Complete Resolution of Neuroendocrine Tumor Soft Tissue Metastases After 177Lu DOTATATE PRRT Induction and Maintenance Therapy.
    Makis W; McCann K; Buteau FA; McEwan AJ
    Clin Nucl Med; 2015 Aug; 40(8):663-6. PubMed ID: 25546219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
    De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
    Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can peptide receptor radionuclide therapy be safely applied in florid bone metastases? A pilot analysis of late stage osseous involvement.
    Sabet A; Khalaf F; Yong-Hing CJ; Sabet A; Haslerud T; Ahmadzadehfar H; Guhlke S; Grünwald F; Biersack HJ; Ezziddin S
    Nuklearmedizin; 2014; 53(2):54-9. PubMed ID: 24777355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hepatic metastases revealing neuroendocrine carcinoma of the esophagus].
    Locher C; Vedrenne B; Jeandel R; Fouladpour C; Glikmanas M; Gatineau-Sailliant G
    Gastroenterol Clin Biol; 1996 Feb; 20(1):114-6. PubMed ID: 8734320
    [No Abstract]   [Full Text] [Related]  

  • 12. Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1-G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases.
    Bertani E; Fazio N; Radice D; Zardini C; Grana C; Bodei L; Funicelli L; Ferrari C; Spada F; Partelli S; Falconi M
    Ann Surg Oncol; 2016 Dec; 23(Suppl 5):981-989. PubMed ID: 27613553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
    Frilling A; Weber F; Saner F; Bockisch A; Hofmann M; Mueller-Brand J; Broelsch CE
    Surgery; 2006 Dec; 140(6):968-76; discussion 976-7. PubMed ID: 17188146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid).
    Davì MV; Bodei L; Francia G; Bartolomei M; Oliani C; Scilanga L; Reghellin D; Falconi M; Paganelli G; Lo Cascio V; Ferdeghini M
    J Endocrinol Invest; 2006 Jun; 29(6):563-7. PubMed ID: 16840837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osseous metastases of gastro-enteropancreatic neuroendocrine tumours. Diagnostic value of intra-therapeutic 177Lu-octreotate imaging in comparison with bone scintigraphy.
    Sabet A; Ezziddin S; Heinemann F; Guhlke S; Muckle M; Willinek W; Biersack HJ; Ahmadzadehfar H
    Nuklearmedizin; 2012; 51(3):95-100. PubMed ID: 22421930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms.
    Partelli S; Bertani E; Bartolomei M; Perali C; Muffatti F; Grana CM; Schiavo Lena M; Doglioni C; Crippa S; Fazio N; Zamboni G; Falconi M
    Surgery; 2018 Apr; 163(4):761-767. PubMed ID: 29284590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic gastric large cell neuroendocrine carcinoma: a case report and review of literature.
    Oberstein PE; Kenney B; Krishnamoorthy SK; Woo Y; Saif MW
    Clin Colorectal Cancer; 2012 Sep; 11(3):218-23. PubMed ID: 22421002
    [No Abstract]   [Full Text] [Related]  

  • 18. Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up.
    Hörsch D; Ezziddin S; Haug A; Gratz KF; Dunkelmann S; Miederer M; Schreckenberger M; Krause BJ; Bengel FM; Bartenstein P; Biersack HJ; Pöpperl G; Baum RP
    Eur J Cancer; 2016 May; 58():41-51. PubMed ID: 26943056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation Contamination Following Cremation of a Deceased Patient Treated With a Radiopharmaceutical.
    Yu NY; Rule WG; Sio TT; Ashman JB; Nelson KL
    JAMA; 2019 Feb; 321(8):803-804. PubMed ID: 30806682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study.
    Baum RP; Kluge AW; Kulkarni H; Schorr-Neufing U; Niepsch K; Bitterlich N; van Echteld CJ
    Theranostics; 2016; 6(4):501-10. PubMed ID: 26941843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.